| Research Topics: |
| INDEX |
| AI-chat 7 |
| PRIME 20 |
| aging 5 |
| brain 8 |
| cancer 12 |
| climate 3 |
| cognition 5 |
| covid-19 2 |
| crime 2 |
| dental 2 |
| diabetes 6 |
| disease 2 |
| economy 3 |
| eyes 1 |
| gender 1 |
| genetics 7 |
| heart 6 |
| kidneys 1 |
| language 1 |
| lungs 2 |
| metabolism 4 |
| microbiome 1 |
| nutrition 7 |
| obesity 1 |
| pain 4 |
| physical 1 |
| politics 2 |
| pollution 1 |
| privacy 1 |
| psychology 7 |
| radiation 1 |
| reproduction 4 |
| rights 1 |
| sleep 1 |
| soc-media |
| stress 1 |
| virus 2 |
| war-confl |
|
Scanned: 1426 Evaluated: 167 Selected: 66 |
| PRIME EYES | ||||||||
Mop14-004 | One-year efficacy and tolerability of 0.05 atropine for myopia control in Estonia: a prospective cohort study | |||||||
| Quote: | Conclusions 0.05 atropine was well tolerated and effective in this population with light irises. Early AL changes may predict 12-month treatment response. These findings support the implementation of 0.05 atropine in routine clinical practice in populations with light irises and highlight the potential for early AL monitoring to guide timely treatment adjustments. | |||||||
| Comment: | A lasting, non-optical treatment for Myopia that alters eyeball Axial Length. | |||||||
| Abstract: | https://www.medrxiv.org/content/10.64898/2026.04.02.26348423v1 | |||||||
| Full Text: | https://www.medrxiv.org/content/10.64898/2026.04.02.26348423v1.full-text | |||||||
| Search Similar: | Brave Mojeek Startpage Dogpile Bing Googl Lycos Utub Yaho | |||||||
| Search Authors: | Delis Linntam Kadi Palumaa Teele Palumaa, | |||||||
|
Javilk's Research Links for Week 14 Updated 04/11/2026-01:28:16 AM What interests you? What have you found? Tell me! Drop me a note to subscribe or submit something. |